Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide/Formoterol Efficacy in Cough Variant Asthma
NCT04171180Phase 4Unknown
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- May 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of budesonide + formoterol in cough variant asthma (CVA) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoint: Proportion of CVA patient with symptom relapse at 6 months. Status: unknown.
02
Drugs
budesonide + formoterol
03
Conditions
cough variant asthma (CVA)
Beyond the preview
Go deeper on NCT04171180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171180.